Predictors of pulmonary involvement in children with COVID-19: How strongly associated is viral load?

Nurhayat Yakut\textsuperscript{1}, Kahraman Yakut\textsuperscript{1}, Zeynep Sarihan\textsuperscript{1}, Irem Kabasakal\textsuperscript{1}, Murat Aydin\textsuperscript{1}, and Nuran Karabulut\textsuperscript{1}

\textsuperscript{1}Sakura Sogo Byoin

June 1, 2022

Abstract

This study aimed to investigate epidemiological, clinical, and laboratory features of children with COVID-19 to identify predictors for pulmonary involvement. We conducted a retrospective, single-center study of pediatric COVID-19 at a tertiary care hospital in Turkey between December 2020 and June 2021. A total of 126 children (70 males, 55.6\%) were examined during the study period. Their mean age was 74.73 ± 81.11 months (range, 1–216 months). The most frequent COVID-19 symptoms were fever (65.9\%), cough (52.4\%), and shortness of breath (18.3\%). Ten patients required noninvasive mechanical ventilation. Sixty-nine patients (54.8\%) had pneumonia. Longer duration of fever and the presence of cough were significantly associated with pulmonary involvement. In children with pneumonia, the C-reactive protein (CRP), procalcitonin levels, erythrocyte sedimentation rate (ESR), and viral load were significantly higher and lymphocyte and thrombocyte counts were significantly lower than in children without pneumonia. The cutoff viral load, CRP, and procalcitonin values for predicting pulmonary involvement were 26.5 cycle threshold (Ct; 95\% confidence interval [CI], 0.54–0.74; sensitivity, 0.65; specificity, 0.56; area under curve [AUC]: 0.647, \( p = 0.005 \)), 7.85 mg/L (95\% CI, 0.56–0.75; sensitivity, 0.66; specificity, 0.64; AUC = 0.656; \( p = 0.003 \)) and 0.105 ng/mL (95\% CI, 0.52–0.72; sensitivity, 0.55; specificity, 0.58; AUC = 0.626; \( p = 0.02 \)), respectively. High CRP, procalcitonin levels, ESR, and viral load and low lymphocyte and thrombocyte counts can predict pulmonary involvement in children with COVID-19, so better management may be provided for good prognosis.
Keywords: COVID-19, children, predictor, viral load, pulmonary involvement.

Introduction

Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rapidly spread worldwide and became a major public health problem. By February 2022, almost 420 million people had been infected throughout the world, with more than 5,840,000 deaths. The clinical spectrum can vary widely from asymptomatic infection to acute respiratory distress syndrome in adults, but it appears to result in milder disease in children. However, most patients hospitalized because of COVID-19 have pulmonary involvement. To date, studies have investigated the association between SARS-CoV-2 viral load and disease severity, mortality, age, comorbidities, and outcomes. Nevertheless, there is no information regarding the associations among viral load, inflammatory biomarkers, and pulmonary involvement in children. Therefore, we aimed to investigate the epidemiological, clinical, and laboratory characteristics of children with COVID-19 and compare the clinical and laboratory features of children with and without pulmonary involvement to identify the factors affecting pulmonary involvement.

Materials and methods

Study design, data collection, and definitions

This prospective, single-center study involved examinations of 126 children with COVID-19 at Başakşehir Çam ve Sakura City Hospital between December 2020 and June 2021.

Among the study participants, COVID-19 diagnosis was confirmed by reverse-transcriptase polymerase chain reaction (PCR) analysis of samples taken from oropharyngeal and nasopharyngeal swabs. The COVID-19 patients were divided into two groups: patients with pulmonary involvement and patients without pulmonary involvement according to clinical symptoms, vital signs (especially respiratory rate, body temperature, and oxygen saturation on room air) chest X-ray, computed tomography (CT) findings and laboratory tests.

The following demographic information, clinical features, laboratory results, and treatment modalities data were examined: age, gender, underlying medical conditions, duration of symptoms and hospitalization, complete blood count, liver and kidney function, inflammatory biomarkers (procalcitonin, erythrocyte sedimentation rate [ESR], and C-reactive protein [CRP]), biologic enzyme levels (lactate dehydrogenase and creatine kinase), D-dimer, coagulation tests, cardiac biomarkers (troponin-T and probrain natriuretic peptide), SARS-CoV-2 PCR, viral load, chest X-ray, and CT scan imaging.

SARS-CoV-2 detection by RT-qPCR and viral load assessment

A combined nasopharyngeal and oropharyngeal specimen collected with a synthetic fiber swab was inserted into a sterile tube containing 3 ml of vNAT (viral nucleic acid isolation tampon; Bio-speedy, Bioeksen, Istanbul, Turkey). Detection of SARS-CoV-2 RNA was accomplished by one-step reverse transcription and real-time PCR targeting SARS-CoV-2-specific RNA-dependent RNA polymerase and N gene fragments using the SARS-CoV-2 Double Gene RT-qPCR kit (Bio-speedy, Bioeksen, Istanbul, Turkey). For internal control, the kit targets the ribonuclease (RNase) P gene. RT-qPCR was performed on the Bio-Rad CFX96 Touch instrument (Hercules, CA, USA) using the following conditions: 52 °C for 5 minutes and 95 °C for 10 seconds, 40 cycles of amplification at 95 °C for 1 second and 55 °C for 1 second. The cycle threshold (Ct) value represents the number of amplification cycles required for the target gene to exceed a threshold level. A low Ct value is indicative of a high viral load. If the Ct value is below 38, it is considered positive for SARS-CoV-2.

Statistical analysis

Statistical analysis was performed using SPSS version 22.0 (IBM, SPSS). Data are summarized as frequencies, medians, and means with standard deviations. Normally distributed data were assessed using means and the Student’s t-test. The nonparametric data’s significance was assessed using the Mann–Whitney U test. The statistical significance of dichotomous outcomes was determined using the chi-square test, Fisher’s exact test, the Fisher–Freeman–Halton test, and Yates’s continuity correction. A multivariate logistic regression
analysis was performed with the variables found to be statistically significant in the univariate analysis. A receiver operating characteristic (ROC) curve analysis was performed to determine the cutoff levels of viral load, CRP, and procalcitonin to predict pulmonary involvement. A value of $p < 0.05$ was considered statistically significant.

The Ethics Committee at Basaksehir Cam ve Sakura City Hospital and the Turkish Ministry of Health (Date: August 4, 2021; Decision no: 161) approved this study.

Results

Patient characteristics and treatment modalities
A total of 126 patients were examined between December 2020 and June 2021. Of all the patients, 70 (55.6%) were male. The mean age was 74.73 ± 81.11 months (range, 1–216 months). On admission, the most common symptoms were fever (83 patients, 65.9%) and cough (66 patients, 52.4%), followed by shortness of breath (23 patients, 18.3%) and myalgia (21 patients, 16.7%). Forty-three patients (34.1%) had underlying medical conditions. All of 10 patients (7.9%) required noninvasive mechanical ventilation had pneumonia. Favipiravir was given to 15 patients (11.9%). Ninety-eight of the patients received broad-spectrum antibiotics for possible bacterial superinfections. The patients’ characteristics and treatment modalities are presented in Table 1. One patient diagnosed with metabolic disease without pulmonary involvement died. All other patients were discharged without any complications.

Laboratory and radiological findings
On admission, the mean white blood cell count, lymphocyte count, and CRP levels were 7903.49 ± 4751.29 thousand cells per mm$^3$ (range, 1030–24,810 thousand cells per mm$^3$), 3302.94 ± 2918.32 thousand cells per mm$^3$ (range, 270–15,890 thousand cells per mm$^3$) and 24.42 ± 47.65 mg/dl (range, 0.1–280 mg/dl), respectively. Lymphopenia and neutropenia were present in 25 (19.8%) and 28 (22.2%) patients, respectively. The patients’ laboratory findings are presented in Table 2.

Chest X-rays were performed in all patients. While 57 (45.2%) of the patients had normal chest X-ray findings, 69 (54.8%) patients had potentially pathological findings. Chest CT scans of 51 patients revealed bilateral ground-glass opacity in 62.7% of them and unilateral ground-glass opacity in 27.5%. The patients’ radiological findings are presented in Table 3.

Factors associated with pulmonary involvement
The patients were divided into two groups: patients with pulmonary involvement (Group 1; n = 69) and patients without pulmonary involvement (Group 2; n = 57). We compared the groups’ epidemiological, clinical, and laboratory characteristics. Group 1’s mean age was significantly higher than that of Group 2. The complaint of cough was significantly more frequent in Group 1. The durations of fever and hospitalization were significantly longer in Group 1 than in Group 2. Lymphopenia was significantly more frequent in Group 1. Favipiravir and low-molecular-weight heparin usage were significantly higher in Group 1 than in Group 2. No other epidemiological or clinical characteristics or treatment modalities demonstrated significant differences between the two groups (Table 1).

According to the univariate analysis, total protein, creatinine levels, CRP, procalcitonin, ESR, and viral load were significantly higher in Group 1 than in Group 2 ($p < 0.05$). Lymphocyte, monocyte, thrombocyte, and eosinophil counts; total bilirubin; troponin T; and folate were significantly lower in Group 1 ($p < 0.05$; Table 2).

In the multivariate logistic regression analysis, lower lymphocyte counts and higher ESR demonstrated a significant association with pulmonary involvement (Table 4).

Predictors of pulmonary involvement
According to the ROC curve analysis, the cutoff levels of viral load, CRP, and procalcitonin were 26.5 Ct (95% CI, 0.54–0.74; sensitivity, 0.65; specificity, 0.56; AUC = 0.647, $p = 0.005$), 7.85mg/L (95% CI, 0.56–0.75; sensitiv...
sensitivity, 0.66; specificity, 0.64; AUC = 0.656, p = 0.003), and 0.105 ng/mL (95% CI, 0.52–0.72; sensitivity, 0.55; specificity, 0.58; AUC = 0.626, p = 0.02), respectively (Figures 1A, 1B, and 1C).

Discussion

This study was aimed to evaluate the clinical and laboratory manifestations that can identify the risk of pulmonary involvement in children with COVID-19. Our study’s major findings indicated that increased CRP (> 7.85 mg/L), procalcitonin (> 0.105 ng/mL), and viral load (< 26.5 Ct) threshold values could be a predictor for pulmonary involvement in children with COVID-19. There is limited research investigating factors associated with pulmonary involvement in children with COVID-19; hence, we believe our study makes an important contribution to the current literature regarding this challenging issue.

Previous studies have reported that COVID-19’s prevalence in children is lower compared to adults, but individuals of all ages can be infected.5,6 Similarly, we found that the age range was 1 to 216 months with a median of 24 months.

To date, previous epidemiological studies have reported that most children had milder disease courses in comparison with adult patients.2,5,7,8 Clinical findings related to COVID-19 usually resemble other respiratory viral infections, with fever and cough being common in most studies. Our findings were similar to those of previous studies.2,5,9

Data from previous studies demonstrate that infants and young children seem to have a high risk of severe disease.2,6 Unlike these reports, we found that older age was associated with increased risk of pulmonary involvement.

Many studies have investigated the association between viral load and disease mortality and severity, but there is no information on the correlation between viral load and pulmonary involvement in SARS-CoV-2-infected children. Previous studies have shown that a higher viral load is associated with increased disease severity and worse outcomes.4,10-12 In addition to these reports, El Zein et al.13 demonstrated that a high viral load was an independent risk factor for in-hospital mortality and intubation. A prospective cohort study by Knudtzen et al.14 conducted on adult patients reported that a higher viral load can predict disease severity in hospitalized patients. Extensive lung involvement was found to be one of the identifying factors associated with increased disease severity.15 Our study added to this knowledge that a high viral load can predict the risk for pulmonary involvement in children with COVID-19.

Elevated inflammatory biomarkers suggesting excessive cytokine production correlate with COVID-19 pneumonia and disease severity. Many mechanisms, including inflammatory biomarker release, alveolar tissue macrophage activation, mononuclear cell accumulation, diffuse alveolar oedema, and interstitial inflammation, can contribute to pulmonary injury and pneumonia.15-18 In this study, we showed that on the one hand, CRP, procalcitonin levels, and ESR were significantly higher and lymphocyte, monocyte, eosinophil, and thrombocyte counts were significantly lower in children with pulmonary involvement than in those without. Our results are consistent with previous studies showing that patients with COVID-19 had decreased platelet, lymphocyte, monocyte, and eosinophil counts and increased CRP levels.19,20 There are reports investigating factors associated with pulmonary involvement in adult patients with COVID-19.21,22 In a retrospective study, Damar Cakirca et al.21 reported that the neutrophil–lymphocyte ratio, the platelet–lymphocyte ratio, the CRP–lymphocyte ratio were higher and the eosinophil–lymphocyte ratio was lower in adult COVID-19 patients with pulmonary involvement than in those without. In another study, Abrishami et al.22 showed that 25 (OH) vitamin D levels were predictive for the amount of lung involvement shown in chest CT. Ferritin was identified as an inflammatory biomarker resulting in immune dysregulation in severe COVID-19 patients.23 In addition to this role of ferritin, Carubbi et al.24 has also demonstrated that higher ferritin levels (above the 25th percentile) were associated with lung involvement severity. Predictors of pulmonary involvement risk in children with COVID-19 were not clearly determined. In the present study, we detected that high CRP, procalcitonin levels, and ESR and low lymphocyte and thrombocyte counts may predict pulmonary involvement risk in children with COVID-19.
Limitations

This study's major limitations were its small sample size and single-center design. Additionally, we did not perform chest CT for pulmonary involvement in every patient.

Conclusions

The identification of predictors for pulmonary involvement in COVID-19 is crucial for guiding appropriate management and generating better disease outcomes. The present study determined that high CRP, procalcitonin levels, ESR, and viral load and low lymphocyte and thrombocyte counts were associated with pulmonary involvement in children with COVID-19. Procalcitonin, CRP levels, and viral load may predict the risk for pulmonary involvement in COVID-19 patients. We think our results could make a significant contribution to this field, about which little is currently known.

Funding: No funding was utilized for this manuscript.

Conflicts of interest: There are no conflicts of interest.

Authors' contribution

Nurhayat Yakut: Conception and design of the study, Acquisition of data, Literature research, writing manuscript, Final approval of the version to be submitted; Kahraman Yakut: Conception and design of the study, Acquisition of data, Analysis and interpretation of data; Zeynep Sarihan: Data collection and processing, Conception and design of the study, Acquisition of data; Irem Kabasakal: Acquisition of data, Analysis and interpretation of data; Murat Aydin: Conception and design of the study, Acquisition of data, Analysis and interpretation of data; Nuran Karabulut: Conception and design of the study, Acquisition of data, Analysis and interpretation of data, Critical review.

All authors read and approved the final manuscript.

References

1. World Health Organization. Coronavirus disease (COVID-19) situation reports [Internet] Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 20 February 2022.
2. Zhu T, Wang Y, Zhou S, Zhang N, Xia L. A comparative study of chest computed tomography features in young and older adults with corona virus disease (COVID-19). J Thorac Imaging. 2020; 35: W97-W101.
3. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323:2052–2059.
4. Maltezou HC, Raftopoulos V, Vorou R, et al. Association Between Upper Respiratory Tract Viral Load, Comorbidities, Disease Severity, and Outcome of Patients With SARS-CoV-2 Infection. J Infect Dis. 2021;223:1132-1138.
5. Escosa-García L, Aguilera-Alonso D, Calvo C, Mellado MJ, Baquero-Artigao F. Ten key points about COVID-19 in children: The shadows on the wall. Pediatr Pulmonol. 2020:55:2576-2586.
6. Parri N, Lenge M, Buonsetso D: Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with Covid-19 in Pediatric Emergency Departments in Italy. N Engl J Med. 2020:383:187-190.
7. Castagnoli R, Votto M, Licari A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatrics. 2020:174:882-889.
8. Hoang A, Chorath K, Moreira A, et al. COVID-19 in 7780 pediatric patients: A systematic review. EClinicalMedicine. 2020:24:100433.
9. Garazzino S, Montagnani C, Donà D, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020:25:2000600.
10. Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;8:e70
11. Bryan A, Fink SL, Gattuso MA, et al. SARS-CoV-2 Viral Load on Admission Is Associated With 30-Day Mortality. Open Forum Infect Dis. 2020;7:ofaa535.
12. Rao SN, Manissero D, Steele VR, Pareja J. A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19. Infect Dis Ther. 2020;9:573–586.
13. El Zein S, Chehab O, Kanj A, et al. SARS-CoV-2 infection: Initial viral load (iVL) predicts severity of illness/outcome, and declining trend of iVL in hospitalized patients corresponds with slowing of the pandemic. PLoS One. 2021;16:e0255981.
14. Knudtzen FC, Jensen TG, Lindvig SO, et al. SARS-CoV-2 viral load as a predictor for disease severity in outpatients and hospitalised patients with COVID-19: A prospective cohort study. PLoS One. 2021;16:e0258421.
15. Gallo Marin B, Aghagoli G, Lavine K, et al. Predictors of COVID-19 severity: A literature review. Rev Med Virol. 2021;31:1-10.
16. Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38-42.
17. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8:e46.
18. Shang W, Dong J, Ren Y, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020;92:2188-2192.
19. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58:1021-1028.
20. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19 a systematic review. Life Sci. 2020;254:117788.

1. Damar Çakırca T, Torun A, Çakırca G, Portakal RD. Role of NLR, PLR, ELR and CLR in differentiating COVID-19 patients with and without pneumonia. Int J Clin Pract. 2021;75:e14781.
2. Abrishami A, Dalili N, Mohammadi Torbat P, et al. Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study. Eur J Nutr. 2021;60:2249-2257.
3. Kappert K., Jahić A., Tauber R. Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases. Biomarkers. 2020;25:616–625.
4. Carubbi F, Salvati L, Alunno A, et al. Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. Sci Rep. 2021;11:4863.

Table 1. The comparison demographic, clinical characteristics and treatment modalities of the patients according to pulmonary involvement.

| Pulmonary involvement | Pulmonary involvement | Total | p       |
|-----------------------|-----------------------|-------|---------|
| No (n=57)             | Yes (n=69)            |       |         |
| Mean ± SD (median)    | Mean ± SD (median)    | Mean ± SD (median) |         |
| Age (months)          |                       |       |         |
| 48.1±72.79 (6)        | 96.74±81.51 (75)      | 74.7±81.11 (24) | 1.000*  |
| Duration of fever     |                       |       |         |
| 1.94±1.16 (2)         | 3.21±2 (2)            | 2.67±1.8 (2) | 1.000*  |
| Duration of cough (median) (days) | Pulmonary involvement | Pulmonary involvement | Total | p |
|---------------------------------|-----------------------|-----------------------|-------|---|
| 3.06±1.98 (2.5) | 3.85±2.41 (3) | 3.64±2.32 (3) | 1.230 |
| Duration of hospitalization (median) (days) | 7.86±3.2 (8) | 9.62±3.99 (9) | 8.83±3.74 (8.5) | 1.004* |
| Gender | n (%) | n (%) | n (%) |
| Female | 22 (%38.6) | 34 (%49.3) | 56 (%44.4) | 2.230 |
| Male | 35 (%61.4) | 35 (%50.7) | 70 (%55.6) | |
| Household close contact | n (%) | n (%) | n (%) |
| No | 19 (%33.3) | 27 (%39.1) | 46 (%36.5) | 3.455 |
| Yes | 37 (%64.9) | 42 (%60.9) | 79 (%62.7) | |
| Underlying condition | n (%) | n (%) | n (%) |
| Gastroesophageal reflux | 1 (%1.8) | 0 (%0) | 1 (%0.8) | |
| Hydronephrosis | 1 (%1.8) | 0 (%0) | 1 (%0.8) | |
| Prematurity | 2 (%3.5) | 1 (%1.4) | 3 (%2.4) | |
| Congenital heart disease | 4 (%7) | 2 (%2.9) | 6 (%4.8) | |
| Asthma | 1 (%1.8) | 4 (%5.8) | 5 (%4) | |
| Type-1 diabetes mellitus | 3 (%5.3) | 1 (%1.4) | 4 (%3.2) | |
| Metabolic diseases | 1 (%1.8) | 4 (%5.8) | 5 (%4) | |
| Congenital neutropenia | 1 (%1.8) | 1 (%1.4) | 2 (%1.6) | |
| Epilepsy | 0 (%0) | 2 (%2.9) | 2 (%1.6) | |
| Immune deficiency | 1 (%1.8) | 3 (%4.3) | 4 (%3.2) | |
| Chronic kidney disease | 0 (%0) | 2 (%2.9) | 2 (%1.6) | |
| Obesity | 0 (%0) | 2 (%2.9) | 2 (%1.6) | |
| Autism | 1 (%1.8) | 0 (%0) | 1 (%0.8) | |
| Down syndrome | 0 (%0) | 1 (%1.4) | 1 (%0.8) | |
| Acute lymphoblastic leukemia | 0 (%0) | 2 (%2.9) | 2 (%1.6) | |
| Mental retardation | 0 (%0) | 1 (%1.4) | 1 (%0.8) | |
| Underlying condition | n (%) | n (%) | n (%) |
| Cerebral palsy | 1 (%1.8) | 0 (%0) | 1 (%0.8) | |
| No | 40 (%70.2) | 43 (%62.3) | 83 (%65.9) | 4.461 |
| Symptoms | n (%) | n (%) | n (%) |
| Yes | 17 (%29.8) | 26 (%37.7) | 43 (%34.1) | 2.336 |
| Fever | 35 (%61.4) | 48 (%69.6) | 83 (%65.9) | |
| Cough | 18 (%31.6) | 48 (%69.6) | 66 (%52.4) | 4.000* |
| Runny nose | 2 (%3.5) | 4 (%5.8) | 6 (%4.8) | 5.435 |
| Sorethroat | 1 (%1.8) | 3 (%4.3) | 4 (%3.2) | |
| Pulmonary involvement | Pulmonary involvement | Total | p |
|-----------------------|-----------------------|-------|---|
| Myalgia               | 6 (%10.5)             | 15 (%21.7) | 21 (%16.7) | 0.150 |
| Abdominal pain        | 1 (%1.8)              | 4 (%5.8) | 5 (%4) | |
| Diarrhoea             | 9 (%15.8)             | 5 (%7.2) | 14 (%11.1) | 0.217 |
| Shortness of breath   | 1 (%1.8)              | 22 (%31.9) | 23 (%18.3) | |
| Favipiravir use       | No                    | 55 (%96.5) | 56 (%81.2) | 111 (%88.1) | 0.018* |
|                       | Yes                   | 2 (%3.5) | 13 (%18.8) | 15 (%11.9) | |
| Azithromycin use      | No                    | 49 (%86) | 50 (%72.5) | 99 (%78.6) | 0.105 |
|                       | Yes                   | 8 (%14) | 19 (%27.5) | 27 (%21.4) | |
| Antibiotherapy        | No                    | 19 (%33.3) | 9 (%13) | 28 (%22.2) | |
|                       | Ampicillin-sulbactam   | 3 (%5.3) | 2 (%2.9) | 5 (%4) | |
|                       | Ampicillin-cefotaxime  | 6 (%8.7) | 18 (%14.3) | |
|                       | Ceftriaxone           | 15 (%26.3) | 14 (%20.3) | 29 (%23) | |
|                       | Cefotaxime            | 4 (%7) | 7 (%10.1) | 11 (%8.7) | |
|                       | Teicoplanin+piperacillin | 1 (%1.4) | 2 (%1.6) | |
|                       | Tazobactam            | |
|                       | Teicoplanin+ceftriaxine| 24 (%34.8) | 25 (%19.8) | |
|                       | Vancomycin+ceftriaxine| 4 (%5.8) | 5 (%4) | |
|                       | Cefepime              | 1 (%1.8) | 2 (%2.9) | 3 (%2.4) | |
| Type of delivery      | Spontaneous vaginal delivery | 23 (%40.4) | 42 (%60.9) | 65 (%51.6) | 0.022* |
|                       | Cesarean delivery     | 34 (%59.6) | 27 (%39.1) | 61 (%48.4) | |
| Non-invasive mechanical ventilation | No | 57 (%100) | 59 (%85.5) | 116 (%92.1) | |
| Neutropenia           | Yes                   | 0 (%0) | 10 (%14.5) | 10 (%7.9) | |
|                       | No                    | 42 (%73.7) | 56 (%81.2) | 98 (%77.8) | 0.430 |
|                       | Yes                   | 15 (%26.3) | 13 (%18.8) | 28 (%22.2) | |
| Lymphopenia           | No                    | 52 (%91.2) | 49 (%71) | 101 (%80.2) | 0.009* |
|                       | Yes                   | 5 (%8.8) | 20 (%29) | 25 (%19.8) | |
| Corticosteroid use    | No                    | 57 (%100) | 58 (%84.1) | 115 (%91.3) | |
|                       | Yes                   | 0 (%0) | 11 (%15.9) | 11 (%8.7) | |
| Low molecular–weight heparin use | No | 53 (%93) | 52 (%75.4) | 105 (%83.3) | 0.016* |
|                       | Yes                   | 4 (%7) | 17 (%24.6) | 21 (%16.7) | |
| Mortality             | No                    | 56 (%98.2) | 69 (%100) | 125 (%99.2) | |
|                       | Yes                   | 1 (%1.8) | 0 (%0) | 1 (%0.8) | |

1 Mann Whitney U test  2 Chi square test  3 Fisher Freeman Halton test  4 Yates’s continuity correction  5 Fisher’s Exact Test *p<0.05
Table 2. The comparison of the laboratory findings of the patients according to pulmonary involvement.

| Variables                     | Pulmonary involvement | Pulmonary involvement | Total          |
|-------------------------------|-----------------------|-----------------------|----------------|
|                               | No (n=57)             | Yes (n=69)             |                |
| Hemoglobin, g/dL              | Mean ± SD (median)    | Mean ± SD (median)    | Mean ± SD (median) |
|                               | 11.33±1.17            | 11.77±1.98            | 11.57±1.89     |
| White blood cells, /mm³       | 8578.95±5273.94 (6890)| 7345.51±4230.06 (5920)| 7903.49±751.29 (6890) |
| Thrombocytes, /mm³ (median)   | 33763.58±122307.08    | 267724.64±132668.08   | 299349.21±13275.6 (299349.21±13275.6) |
| Lymphocyte, /mm³ (median)     | 4305.26±3437.42 (3280)| 2474.93±2094.52 (1790)| 3302.94±2918.32 (2890) |
| Neutrophil, /mm³ (median)     | 3262.46±3263.51 (2060)| 4090.29±3371.47 (3150)| 3715.79±335.58 (3715.79±335.58) |
| Monocytes, /mm³               | 1017.02±607.15 (890)  | 685.51±502.67 (560)   | 835.48±574.5 (710) |
| Eosinophil, /mm³ (median)     | 128.25±179.4 (60)     | 77.25±121.21 (20)     | 100.32±151.85 (40) |
| MCV, fL                       | 84.2±8.31 (84)        | 82.43±7.37 (82)       | 83.29±7.83 (83)  |
| Erythrocyte sedimentation rate, mm/h (median) | 14.09±9.97 (9) | 27.17±21.69 (24) | 21.1±18.4 (16) |
| C-reactive protein, mg/L (median) | 12.77±27.23 (2.4) | 33.88±57.78 (9.4) | 24.42±47.65 (4.5) |
| Procalcitonin, ng/ml (median) | 0.31±1.09 (0.1)      | 0.81±2.1 (0.1)       | 0.58±1.72 (0.1) |
| Alanine aminotransferase, IU/L (median) | 39.39±84.61 (21.5) | 62.16±220.22 (22) | 51.96±172.9 (22) |
| Aspartate aminotransferase, IU/L (median) | 73.3±197.32 (37.5) | 72.42±221.26 (37) | 72.82±210.04 (37) |
| Lactate dehydrogenase, IU/L (median) | 321.21±229.33 (285) | 350.21±208.74 (291) | 337.01±217.93 (287) |
| INR (median)                  | 1.09±0.26 (1)        | 1.07±0.1 (1.1)       | 1.08±0.19 (1) |
| D-dimer, μg/FEU/ml (median)   | 1.27±1.57 (0.7)      | 1.57±3.79 (0.5)      | 1.43±2.99 (0.6) |
| Total bilirubin, mg/dL (median) | 2.55±8.59 (0.4)     | 1.18±4.04 (0.3)      | 1.79±6.68 (0.3) |
| Indirect bilirubin, mg/dL (median) | 0.8±1.47 (0.2)      | 0.48±1.45 (0.2)      | 0.62±1.46 (0.2) |
| Total protein, g/L (median)   | 60.92±7.69 (60)      | 66.08±7.67 (67)      | 63.74±8.07 (64) |
| Albumin, g/L                  | 41.22±4.33           | 41.97±4.72           | 41.62±4.55     |
| Creatine kinase, U/L (median) | 99.18±87.93 (75)     | 468.52±2922.04 (87.5)| 318.78±2254.25 (80) |
| ProBNP, pg/ml (median)        | 873.04±1365.29 (314.5) | 406.81±823.8 (153) | 595.4±1093.32 (217) |
| Troponin T, ng/L (median)     | 24.2±24.17 (15)      | 11.88±15.07 (4.9)    | 17.25±20.41 (5.8) |
| Urea mg/dl (median)           | 16.63±7.93 (16.5)    | 20.97±16.22 (18.1)   | 19.01±13.27 (17.6) |
| Creatinine, mg/dl (median)    | 0.34±0.17 (0.3)      | 0.51±0.42 (0.4)      | 0.43±0.34 (0.3) |
| Iron, μg/dl (median)          | 63.19±46.03 (52)     | 50.17±32.53 (36)     | 55.94±39.43 (44.5) |
| Ferritin, ng/ml (median)      | 325.33±484.97 (167)  | 350.85±534.03 (163)  | 339.39±510.83 (167) |
| Folate, ng/ml (median)        | 16.24±8.49 (15.2)    | 12.25±8.4 (10.4)     | 14.03±8.63 (12.6) |
| 25-hydroxyvitamin D, ng/ml (median) | 23.98±14.03 (20.5) | 22.72±18.94 (15.2)  | 23.26±16.93 (19) |
| Vitamin B12, pg/ml (median)   | 372.39±178.15 (358)  | 480.03±387.23 (349.5)| 432.42±315.8 (353.5) |
| IL-6, pg/ml (median)          | 17.45±24.69 (6.8)    | 15.23±22.87 (7.1)    | 16.09±23.46 (7) |
| Viral load, Ct                | 28±5.2               | 25.4±5.61            | 26.8±5.52      |

*Student t test *Mann Whitney U test *p<0.05

Table 3. Radiological findings of the patients with COVID 19.

|                          | n  | %  |
|--------------------------|----|----|
| Chest X-ray (n=126)      |    |    |
| Normal                   | 57 | 45.2|
| Right paracardiac infiltration | 22 | 17.5|
| Bilateral interstitial infiltration | 30 | 23.8|
| Peribronchial infiltration | 8  | 6.3 |
| Bilateral paracardiac infiltration | 6  | 4.8 |
| Consolidation            | 2  | 1.6 |
| Right pleural effusion   | 1  | 0.8 |
Chest computed tomography (n=51)  
| Condition                      | n | %  |
|--------------------------------|---|----|
| Bilateral ground-glass opacity | 32| 62,7|
| Right ground-glass opacity     | 10| 19,6|
| Left ground-glass opacity      | 4 | 7,9 |
| Consolidation                  | 5 | 9,8 |

Table 4. Multivariate logistic regression analysis examining factors affecting pulmonary involvement.

|                      | OR   | 95% CI        | p    |
|----------------------|------|---------------|------|
| Lymphocyte count     | 1,000| 0,999-1,000   | 0,036*|
| Erythrocyte sedimentation rate | 1,061| 1,015-1,108 | 0,008*|
| Constant             | 0,935|               | 0,924|

*p<0.05

Figure 1A,B,C. ROC curves for viral load, CRP and procalcitonin.